Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

November 16, 2020November 16, 2020

US Trial Testing Mylotarg Plus Venclexta for AML Now Enrolling Participants

News

A Phase 1b study testing Mylotarg (gemtuzumab ozogamicin) plus Venclexta (venetoclax) for adults with relapsing or refractory acute myeloid leukemia (AML) is currently enrolling patients. The trial (NCT04070768) is taking place across four clinical ... Read more

October 29, 2020October 29, 2020

Dosing Begins in Phase 1 Trial Testing PRT1419 for Advanced AML, Other Blood Cancers

News

The first patient has been dosed in a Phase 1 trial testing the investigational cancer therapy PRT1419 in patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML), ... Read more

September 24, 2020September 24, 2020

Dosing Begins in Phase 1 Trial Testing Immune-Onc’s IO-202 for Advanced AML, CMML

News

The first patient has been dosed in Immune-Onc Therapeutic’s Phase 1 clinical trial of IO-202, its lead antibody treatment candidate for advanced acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). The trial (NCT04372433), ... Read more

April 16, 2020April 16, 2020

COVID-19 Pandemic Stops Phase 2 Trial of Ficlatuzumab Combo Therapy for AML

News

The Phase 2 CyFi-2 study assessing the safety and efficacy of ficlatuzumab (previously AV-299) combined with standard chemotherapy in patients with hard-to-treat acute myeloid leukemia (AML) has been discontinued ... Read more

March 10, 2020March 10, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

January 31, 2020February 6, 2020

First AML Patient Dosed in Phase 1 Trial of Cellectis’ CAR T-cell Therapy, UCART123

News

Cellectis has started dosing participants in its Phase 1 trial assessing the safety and clinical activity of an updated version of UCART123, its CAR T-cell therapy for patients with ... Read more

November 12, 2019November 12, 2019

Quizartinib Not Recommended in Europe as Therapy for Relapsed or Refractory AML with FLT3-ITD Mutation

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has issued a negative opinion on quizartinib, being developed by Daiichi Sankyo. ... Read more